Replies to post #116001 on Biotech Values

[acgood]

re: copaxone trial

Haven't gotten to listen yet- was that Wheeler's phrasing? Because that would leave open the chance that sandoz/mnta are indeed planning either of the possibilities you mentioned- a bioequivlance trial or a trial targeting EU/ROW approvals